Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

6 treatments under study, led by Loxenin

Research Leaders

6 sponsors active, led by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 4 (1)

Trial Status

Withdrawn1
Completed1
Terminated1
Unknown1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT02204813Phase 1Completed

To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery

NCT01597531Phase 4Terminated

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

NCT01930448Withdrawn

Mechanisms of Diabetes Control After Weight Loss Surgery, Sub-study #1

NCT01559792Unknown

Band to Bypass - Metabolism Kinetics in Gastric Bypass and Banding

Showing all 4 trials

Research Network

Common Treatments

  • Loxenin1
  • Liraglutide1
  • Liraglutide Orlistat1
  • Hixenin1
  • Extra Hixenin1

Active Sponsors

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1
  • East Carolina University1
  • St. Luke's-Roosevelt Hospital Center1
  • National Institutes of Health (NIH)1
  • Washington University School of Medicine1

Top Investigators

Related Conditions

  • Type 2 Diabetes2
  • Rouxeny Gastric Bypass1
  • Bariatric Surgery1
  • Gastric Bypass1
  • Bypass Gastric1

Activity Timeline